newsfilter
← Latest News
GlobeNewswire·

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS™ Treatment December 1, 2025

  • BrainsWay Ltd. will host a virtual Analyst & Investor Day on Monday, December 1, 2025, at 10:00 AM ET.
  • The event will feature Owen Scott Muir, MD, discussing unmet medical needs & clinical experience with Deep TMS™.
  • Michael Gershenzon, CEO of Stella MSO, will discuss the strategic minority-stake investment in his organization.
  • Presentations will cover the patented Deep TMS technology & the potential impact of its accelerated protocol.
  • Deep TMS is a noninvasive treatment using magnetic fields to address depression, OCD, & smoking addiction.
  • A live question & answer session will follow the formal presentations.
  • BrainsWay holds three FDA-cleared indications for major depressive disorder, obsessive-compulsive disorder, & smoking addiction.
  • Additional clinical trials for Deep TMS in various psychiatric, neurological, & addiction disorders are underway.
  • The press release includes standard forward-looking statement disclaimers regarding risks & uncertainties.
  • Contact information for BrainsWay CFO Ido Marom & investor relations contact Brian Ritchie is provided.